EPS: As of FY2025 Q2, the actual value is USD -0.5, beating the estimate of USD -0.535.<h3>Segment Revenue</h3><ul><li>Bicara Therapeutics Inc. has not generated any revenue from product sales or other sources since its inception in December 2018.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: For the three months ended June 30, 2025, the net loss was $27.4 million, compared to $17.0 million for the same period in 2024. For the six months ended June 30, 2025, the net loss was $64.2 million, compared to $29.6 million for the same period in 2024.</li><li>Operating Expenses: Total operating expenses for the three months ended June 30, 2025, were $32.0 million, compared to $19.8 million for the same period in 2024. For the six months ended June 30, 2025, operating expenses were $73.8 million, compared to $35.1 million for the same period in 2024.</li><li>Research and Development Expenses: For the three months ended June 30, 2025, research and development expenses were $24.8 million, compared to $15.8 million for the same period in 2024. For the six months ended June 30, 2025, research and development expenses were $59.1 million, compared to $27.9 million for the same period in 2024.</li><li>General and Administrative Expenses: For the three months ended June 30, 2025, general and administrative expenses were $7.2 million, compared to $3.9 million for the same period in 2024. For the six months ended June 30, 2025, general and administrative expenses were $14.7 million, compared to $7.3 million for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: For the six months ended June 30, 2025, net cash used in operating activities was $53.7 million, compared to $27.5 million for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: For the six months ended June 30, 2025, net cash provided by financing activities was $0.6 million, compared to $0.9 million for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Cash and Cash Equivalents: As of June 30, 2025, Bicara Therapeutics Inc. had cash and cash equivalents of $436.6 million.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: Bicara Therapeutics Inc. plans to continue advancing the clinical development of its lead program, ficerafusp alfa, and expects expenses and operating losses to increase substantially as it conducts current and future clinical trials, continues research and development activities, and seeks regulatory approvals.</li><li>Non-Core Business: The company may seek to grow its business through acquisitions or investments in new or complementary businesses, products, or technologies, through the licensing of products or technologies from third parties or other strategic alliances.</li><li>Priority: Bicara Therapeutics Inc. anticipates that its existing cash and cash equivalents will be sufficient to fund its operations into the first half of 2029.</li></ul>

Bicara Therapeutics | 10-Q: FY2025 Q2 EPS Beats Estimate at USD -0.5